Chief Medical Officers

Pharming appoints Anurag Relan as Chief Medical Officer and Robert Friesen as Chief Scientific Officer

Retrieved on: 
Friday, June 18, 2021

LEIDEN, The Netherlands, June 18, 2021 /PRNewswire/ -- Pharming Group N.V. ("Pharming" or "the Company") (Euronext Amsterdam: PHARM/Nasdaq: PHAR)announces the appointment of Anurag Relan as Chief Medical Officer (CMO), effective immediately, and Robert Friesen as Chief Scientific Officer, effective from 1 August 2021.

Key Points: 
  • LEIDEN, The Netherlands, June 18, 2021 /PRNewswire/ -- Pharming Group N.V. ("Pharming" or "the Company") (Euronext Amsterdam: PHARM/Nasdaq: PHAR)announces the appointment of Anurag Relan as Chief Medical Officer (CMO), effective immediately, and Robert Friesen as Chief Scientific Officer, effective from 1 August 2021.
  • Anurag and Robert will be the successors of Bruno Giannetti, who was Chief Operating Officer (2006 - 2019) and Chief Medical Officer from 2019.
  • Anurag Relan is currently Vice President, Clinical Research and Medical Affairs at Pharming, having held a number of roles within the Company during the past 15 years.
  • Prior to his work at Pharming, he was in clinical practice while also teaching medical residents/students.

Onconova Therapeutics Announces the Appointment of Mark Gelder, M.D., as Chief Medical Officer

Retrieved on: 
Tuesday, June 1, 2021

will be joining Onconova as Chief Medical Officer (CMO), effective as of June 14, 2021.

Key Points: 
  • will be joining Onconova as Chief Medical Officer (CMO), effective as of June 14, 2021.
  • He will add great depth to our management team, said Steven M. Fruchtman, M.D., President and Chief Executive Officer of Onconova.
  • I am thrilled that Mark will be joining Onconova and eager to begin working together.
  • Dr. Gelder is an accomplished industry leader with more than 35 years of experience in clinical development, medical affairs, and medical marketing.

Karius Strengthens Leadership Team, Names Former CDC Exec as Chief Medical Officer

Retrieved on: 
Thursday, May 27, 2021

REDWOOD CITY, Calif., May 27, 2021 /PRNewswire/ -- Karius , the world leader in liquid biopsy for infectious diseases, announced Bradley Perkins, MD, as the company's new Chief Medical Officer (CMO).

Key Points: 
  • REDWOOD CITY, Calif., May 27, 2021 /PRNewswire/ -- Karius , the world leader in liquid biopsy for infectious diseases, announced Bradley Perkins, MD, as the company's new Chief Medical Officer (CMO).
  • Dr. Perkins most recently served as the co-founder and Chief Medical Officer at The Commons Project Foundation, helping establish it as the premier non-profit organization building global digital services and platforms for the common good.
  • I'm excited about the potential for it to scale even further, allowing us to impact lives on a global level."
  • The Karius Test helps clinicians avoid invasive, low-yield, and sequential diagnostic tests that can delay treatment for the most vulnerable hospitalized patients.

Xcovery Announces the Appointment of Giovanni Selvaggi as Chief Executive Officer

Retrieved on: 
Thursday, March 18, 2021

Xcovery Holdings, Inc. , an oncology focused bio-pharmaceutical company, today announced that Giovanni Selvaggi, M.D., has been appointed as the Chief Executive Officer (CEO), replacing Li Mao, M.D., who is leaving for personal reasons.

Key Points: 
  • Xcovery Holdings, Inc. , an oncology focused bio-pharmaceutical company, today announced that Giovanni Selvaggi, M.D., has been appointed as the Chief Executive Officer (CEO), replacing Li Mao, M.D., who is leaving for personal reasons.
  • Dr. Selvaggi will also continue as Xcoverys Chief Medical Officer (CMO).
  • View the full release here: https://www.businesswire.com/news/home/20210318005884/en/
    Giovanni is the right leader for Xcovery, said Lieming Ding, M.D., Chairman of the Board.
  • From March 2019, Dr. Selvaggi has been the Chief Medical Officer at Xcovery.

Cognoptix Appoints New Chief Medical Officer, Dr. Carl Sadowsky, MD, And Chief Financial Officer, Mike Kaswan, MBA, To Management Team

Retrieved on: 
Monday, January 4, 2021

Dr. Carl H. Sadowsky, MD will serve as the company's new Chief Medical Officer (CMO) and Mike Kaswan, MBA will be Cognoptix's Chief Financial Officer (CFO).

Key Points: 
  • Dr. Carl H. Sadowsky, MD will serve as the company's new Chief Medical Officer (CMO) and Mike Kaswan, MBA will be Cognoptix's Chief Financial Officer (CFO).
  • He served on the scientific review board for Alzheimer's Drug Discovery Foundations (ADDF) and serves on the Alzheon scientific advisory board.
  • Mike Kaswan brings over 25 years of experience as a senior finance, chief executive, and venture capital officer of rapidly growing healthcare companies.
  • "Both will be tremendous assets to Cognoptix, rounding out the formidable strength of the Cognoptix team," added Dr. Wilke.

Tampa General Hospital Names Dr. Peggy Duggan New Chief Medical Officer

Retrieved on: 
Monday, November 2, 2020

TAMPA, Fla., Nov. 2, 2020 /PRNewswire/ --Tampa General Hospital has named Dr. Peggy Duggan as its new executive vice president and chief medical officer (CMO).

Key Points: 
  • TAMPA, Fla., Nov. 2, 2020 /PRNewswire/ --Tampa General Hospital has named Dr. Peggy Duggan as its new executive vice president and chief medical officer (CMO).
  • Duggan will officially begin her new role at Tampa General Hospital, one of the largest and most comprehensive academic medical centers in the nation, on January 24, 2021.
  • During these 15 years, she practiced as a breast surgeon and medical director of the breast center, and ultimately became the chief medical officer for the Brigham and Women's Faulkner Hospital.
  • "I am very pleased to announce the appointment of Dr. Peggy Duggan as CMO of Tampa General," said Tampa General Hospital President and CEO John Couris.

DGAP-News: HepaRegeniX GmbH hires industry veteran Dr David Shapiro as Senior Medical Advisor

Retrieved on: 
Tuesday, October 20, 2020

Tubingen (Germany), October 20, 2020 - HepaRegeniX GmbH, a preclinical stage company developing novel therapies for the treatment of acute and chronic liver diseases, announced today that Dr David Shapiro will join the company as Senior Medical Advisor.

Key Points: 
  • Tubingen (Germany), October 20, 2020 - HepaRegeniX GmbH, a preclinical stage company developing novel therapies for the treatment of acute and chronic liver diseases, announced today that Dr David Shapiro will join the company as Senior Medical Advisor.
  • Dr. Shapiro has over 30 years of experience in the pharmaceutical and biotechnology industries.
  • Formerly, Dr Shapiro was Chief Medical Officer (CMO) and Head of Research and Development at Intercept Pharmaceuticals from 2007 through 2019.
  • Dr. David Shapiro, Senior Medial Advisor of HepaRegeniX, noted: "These are very exciting times for liver disease physicians and patients, with many innovative therapeutic options to alleviate and abate many indications.

Doc Patels' Appoints Dakota Sullivan Chief Executive Officer and Names Dr. Rachna Patel as Chief Medical Officer

Retrieved on: 
Tuesday, September 15, 2020

OAK BROOK, Ill., Sep 15, 2020 /PRNewswire/ --Doc Patels' LLC, a leading provider of organic, broad-spectrum CBD products, today announced that Dakota Sullivan has been appointed chief executive officer.

Key Points: 
  • OAK BROOK, Ill., Sep 15, 2020 /PRNewswire/ --Doc Patels' LLC, a leading provider of organic, broad-spectrum CBD products, today announced that Dakota Sullivan has been appointed chief executive officer.
  • Dr. Rachna Patel, currently chief executive officer, has been appointed to the newly created position of chief medical officer.
  • Prior to joining Doc Patels', Sullivan was co-founder, CEO of Calyx Brands, Inc, a wholesale distributor of THC and CBD products.
  • With the appointment, Dr. Rachna Patel will be stepping into the new role of chief medical officer.